Miricorilant

DB16234InvestigationalSmall molecule

Miricorilant is under investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent Weight Gain While Taking...

Mechanism: Pharmacologically active on Mineralocorticoid receptor and Glucocorticoid receptor
Curator reviewed
Formula / weight: C₂₄H₂₃F₃N₂O₂ · 428.455 g/mol (avg)
Code names: CORT-118335

Resolves to

Compound

UNII311Y5GV21MCAS1400902-13-7ChEMBLCHEMBL4297602

Structure

InChIKeyGVVUZBSCYAVFTI-IYARVYRRSA-NSMILESFC(F)(F)C1=CC(CC2=C(NC(=O)NC2=O)[C@H]2CC[C@@H](CC2)C2=CC=CC=C2)=CC=C1

Targets

P08235NR3C2P04150NR3C1

Transporters

Q9UNQ0ABCG2

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1TransporterSubstrate / inhibitor direction, not just membership

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

13+ReferencesStructured and connected to the statements they support

Which drugs share a target with Miricorilant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In